Splenda is comprised of the high-potency artificial sweetener sucralose (1.1%) and the fillers maltodextrin and glucose. Splenda was administered by oral gavage at 100, 300, 500, or 1000 mg/kg to male Sprague-Dawley rats for 12-wk, during which fecal samples were collected weekly for bacterial analysis and measurement of fecal pH. After 12-wk, half of the animals from each treatment group were sacrificed to determine the intestinal expression of the membrane efflux transporter P-glycoprotein (P-gp) and the cyto-chrome P-450 (CYP) metabolism system by Western blot. The remaining animals were allowed to recover for an additional 12-wk, and further assessments of fecal microflora, fecal pH, and expression of P-gp and CYP were determined. At the end of the 12-wk treatment period, the numbers of total anaerobes, bifido-bacteria, lactobacilli, Bacteroides, clostridia, and total aerobic bacteria were significantly decreased; however, there was no significant treatment effect on enterobacteria. Splenda also increased fecal pH and enhanced the expression of P-gp by 2.43-fold, CYP3A4 by 2.51-fold, and CYP2D1 by 3.49-fold. Following the 12-wk recovery period, only the total anaerobes and bifido-bacteria remained significantly depressed, whereas pH values, P-gp, and CYP3A4 and CYP2D1 remained elevated. These changes occurred at Splenda dosages that contained sucralose at 1.1-11 mg/kg (the US FDA Acceptable Daily Intake for sucralose is 5 mg/kg). Evidence indicates that a 12-wk administration of Splenda exerted numerous adverse effects, including (1) reduction in beneficial fecal microflora, (2) increased fecal pH, and (3) enhanced expression levels of P-gp, CYP3A4, and CYP2D1, which are known to limit the bioavailability of orally administered drugs. The artificial high-potency sweetening compound sucralose is a chlorinated disaccharide with the chemical formula 1,6-dichloro-1,6-dideoxy-β-D-fructofuranosyl-4-chloro-4-deoxy-α-D-galactopyranoside (Federal Register, 1998). Sucralose is ubiquitous in the world food supply as an ingredient in over 4000 products, including tabletop sweeteners and sugar substitutes (e.g., Splenda), baked goods, beverages such as soft drinks, coffee, and tea, breakfast cereals, chewing gum, desserts , and pharmaceutical products (International Food Information Council Foundation, 2004). Because sucralose is approximately 600 times sweeter than sucrose by weight (Schiffman & Gatlin, 1993; Schiffman et al., 2008), sucralose formulations such as Splenda utilize fillers including malto-dextrin and glucose for volume. In acidic environments and at elevated temperatures, sucralose hydrolyzes over time to its constituent monosaccharides 1,6-dichloro-1,6-dideoxyfructose (1,6-DCF) and 4-chloro-4-deoxy-galactose (4-CG) (Grice & Goldsmith, 2000). Pharmacokinetics and metabolism studies of sucralose have shown that the majority of ingested sucralose (approximately 65-95% depending on the species) is not absorbed from the gas-trointestinal tract (GIT) but rather was excreted in the feces (Sims et al., 2000; Roberts et al., 2000; Federal Register, 1998). The low absorption of sucralose from the GIT is surprising, because this sweetener is an organochlorine molecule with appreciable lipid solubility (Miller, 1991; Wallis, 1993; Yatka et al., 1992). The low bioavailability of sucralose suggests that it is likely extruded back into the intestinal lumen during first-pass metabolism in the GIT. The concentrations of many orally consumed compounds including drugs and nutrients are reduced during first-pass metabolism in the small intestine by the membrane efflux transporter P-glycoprotein (P-gp) and the cyto-chrome P-450 (CYP) metabolism system. P-gp extrudes these compounds from the intestinal walls back to the lumen and/or CYP enzymes metabolize the compounds. P-gp and CYP are both involved in xenobiotic detoxification in the intestine and liver of many diverse chemicals, including organochlorine compounds (Lanning et al.